Sorry, you need to enable JavaScript to visit this website.
Home Science Coronavirus Resources Partnerships

Partnerships and Anti-Infective Efforts

Anti-infective Efforts - Sharing azithromycin data:

In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers published a review in Clinical Pharmacology and Therapeutics which assesses published in vitro and clinical data regarding azithromycin as an agent with antiviral properties. This open access review may serve to facilitate the use of azithromycin in future research on COVID-19. Azithromycin is not approved for the treatment of viral infections.

Research that may inform future vaccination guidelines

Pfizer Inc. and the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group launched two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2. Pfizer's collaboration agreement with Liverpool provides funding and in-kind laboratory testing support for this research.

Collaborating to address COVID-19

As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem ranging from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis.

If you’re a researcher interested in collaborating, contact [email protected]

Existing collaborations:

BioNTech
a global collaboration agreement to co-develop BioNTech’s potential first-in-class, mRNA-based coronavirus vaccine program aimed at preventing COVID-19 infection
Rega Institute for Medical Research
at the Katholieke Universiteit Leuven, Belgium, assessing the antiviral activity of SARS-CoV-2 3CL protease inhibitors in Vero cell assays
Dr. Andrew Mesecar
at Purdue University, assessing small molecule selectivity against related proteases and characterizing the binding mode of compounds using X-ray crystallography
Dr. Matthew Frieman
at the University of Maryland School of Medicine, assessing the activity of SARS-CoV-2 3CL protease inhibitors in Vero cell assays
Dr. Jun Wang
at the University of Arizona College of Pharmacy, assessing enzymatic activity in a SARS-CoV-2 3CL assay and establish antiviral activity in cellular assays
Dr. Ralph Baric
at the UNC, screening Pfizer’s lead compound and additional compounds for antiviral activity in a primary human airway epithelial cell assay
Dr. Meike Dittmann
at NYU – Langone, characterizing if our candidate protease inhibitor inhibits replication of SARS-CoV-2 in a 3D primary human airway epithelial cell culture system. 
Arnab Chatterjee
at The Scripps Research Institute, assessing antiviral activity of our lead compound in cellular assays
SECURE-IBD Database
an international, pediatric and adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients Pfizer is proud to support.

 

For additional information about Pfizer, please see our filings with the U.S. Securities and Exchange Commission, including the information provided in the sections captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”.